McKesson Corporation (MCK)
NYSEHealth CareMedical - DistributionSnapshot 2026-09-04
$907.99-1.45%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DistributionSnapshot 2026-09-04
QuarterlyIQ Insights · MCK
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks MCK against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Met or beat guidance 100% of the last 1 guided quarters · 43.9% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Maintain and deliver on long-term adjusted earnings per diluted share growth targets of 13% to 16%.
Stated as a priority in 6 of last 6 quarters. Management consistently reaffirmed long-term adjusted EPS growth targets of 13% to 16%. Fiscal 2026 full year adjusted EPS grew 18% to $39.11, and fiscal 2027 guidance raised to $44.20-$45.00 indicating 13%-15% growth. The trajectory is delivering against the long-term growth commitment.
“Reaffirming long-term Adjusted Earnings per Diluted Share growth target of 13% to 16%.”
“Reaffirming long-term Adjusted Earnings per Diluted Share growth target of 13% to 16%.”
“Reaffirming long-term Adjusted Earnings per Diluted Share growth target of 13% to 16%.”
“Reaffirming long-term Adjusted Earnings per Diluted Share growth target of 13% to 16%.”
“Reaffirming long-term Adjusted Earnings per Diluted Share growth target of 13% to 16%.”
“Reaffirming long-term Adjusted Earnings per Diluted Share growth target of 13% to 16%.”
Drive growth in Oncology & Multispecialty segment through acquisitions and increased specialty distribution.
Stated as a priority in 6 of last 6 quarters. Oncology & Multispecialty segment revenues grew from $12.0 billion in 2025-Q2 to $14.2 billion in 2026-Q2, a 33% increase driven by acquisitions and specialty distribution. Adjusted segment operating profit increased 41% in 2026-Q2. Management is delivering growth consistent with stated priorities.
Continue portfolio optimization by divesting non-core businesses including European operations and Canadian retail.
Stated as a priority in 5 of last 6 quarters. Management completed divestitures of Norwegian retail and distribution businesses by January 2026 and Canadian Rexall and Well.ca retail businesses by December 2024. These actions reflect ongoing portfolio optimization efforts. The trajectory shows consistent execution on divestiture plans.
“On January 30, 2026, McKesson closed the transaction to sell its retail and distribution businesses in Norway, representing the final phase to fully exit its European operations.”
Expand share repurchase program and return capital to shareholders through accelerated share repurchases and dividends.
Stated as a priority in 4 of last 6 quarters. Management increased share repurchase authorization by $5.0 billion to $7.7 billion as of April 2026 and completed $2.5 billion in share repurchases in 2026-Q2. Dividend per share increased 15% in 2026-Q2. The trajectory shows active capital return consistent with stated priorities.
Advance planned separation of Medical-Surgical Solutions segment into an independent company to unlock value and focus portfolio.
Stated as a priority in 5 of last 6 quarters. Management announced intent to separate Medical-Surgical Solutions segment in 2025-Q2 and has advanced the separation through transition service agreements and minority interest sale by 2026-Q2. The trajectory shows consistent progress toward separation.
“McKesson continued to advance its planned separation of Medical-Surgical Solutions segment.”
Over the trailing year it converted -1.09x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 32% of the time over the next year (vs 54% for the rest of the cohort, n=2490).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity, the broad stock market (low R² over the window).
13 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“Oncology & Multispecialty revenues were $14.2 billion, an increase of 33%, driven by growth in provider solutions and specialty distribution, including contributions from acquisitions.”
“Oncology & Multispecialty revenues increased 35%, driven by growth in provider solutions and specialty distribution, including acquisitions.”
“Oncology & Multispecialty revenues increased 35%, driven by growth in provider solutions and specialty distribution, including acquisitions.”
“Oncology & Multispecialty revenues increased 37%, driven by growth in provider solutions and specialty distribution, including acquisitions.”
“Oncology & Multispecialty revenues increased 32%, driven by increased provider and specialty distribution growth and contributions from acquisitions.”
“Oncology and specialty products growth including acquisitions contributed to revenue increases.”
“McKesson closed the transaction to sell its retail and distribution businesses in Norway on January 30, 2026.”
“McKesson closed the transaction to sell its Norwegian retail and distribution businesses to NorgesGruppen on January 30, 2026.”
“McKesson closed the transaction to sell its Canada-based Rexall and Well.ca retail businesses on December 30, 2024.”
“McKesson announced an agreement to sell its Canada-based Rexall and Well.ca retail businesses.”
“McKesson completed $2.5 billion share repurchases, including $2.25 billion under the accelerated share repurchase program.”
“McKesson entered into a $2.25 billion accelerated share repurchase program.”
“Board approved a $5.0 billion increase to the share repurchase program, bringing total authorization to $7.7 billion as of April 2026.”
“McKesson returned $2.1 billion of common stock repurchases in first nine months of fiscal 2026.”
“McKesson advanced its planned separation of Medical-Surgical Solutions segment by implementing transition service agreements.”
“Announced intent to separate Medical-Surgical Solutions segment into an independent company.”
“Announced intent to separate Medical-Surgical Solutions segment into an independent company.”
“Announced intent to separate Medical-Surgical Solutions segment into an independent company.”